Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes

June 28, 2010 By Bio-Medicine.Org

PARSIPPANY, N.J., June 28 /PRNewswire/ — Preliminary results
of a pre-specified subgroup study analysis of patients with
diabetes and hypertension demonstrated that the investigational
triple combination therapy of olmesartan medoxomil / amlodipine /
hydrochlorothiazide (40/10/25 mg) resulted in a statistically
significant greater Least Squares (LS) mean reduction in blood
pressure from baseline at week 12 (37.9/22.0 mm Hg versus
26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as
compared to corresponding dual combination therapy [olmesartan
medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40
mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and
hydrochlorothiazide (25 mg)].(1) Blood pressure is more difficult
to control among patients with hypertension and diabetes compared
to patients with hypertension alone.(2) These findings were
presented today during a poster presentation at the American
Diabetes Association (ADA) 70th Annual Scientific Sessions in Orlando, FL.

This analysis of the TRINITY study (Triple Therapy
with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in
Hypertensive Patients
Study) also demonstrated that the investigational
triple combination therapy (40/10/25 mg) enabled more patients with
hypertension and diabetes to achieve blood pressure goal of
<130/80 mm Hg at week 12 as compared to corresponding dual
combination therapies (41.1 percent in the triple combination group
versus 10.1 to 16.3 percent in the dual combination groups, P less
than or equal to 0.0002).(1) Baseline blood pressures for those
patients receiving the triple combination therapy and corresponding
dual combination therapies were 170.7/98.3 mm Hg and
170.7-173.1/97.8-99.3 mm Hg, respectively.(1)

‘/>”/>

SOURCE

Related Articles Read More >

Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech